- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05893316
UroCAD para la evaluación de la hematuria: un estudio multicéntrico prospectivo
Evaluación de la hematuria mediante la secuenciación del genoma completo del ADN celular exfoliado con orina, un estudio prospectivo multicéntrico
Hematuria is recognized as an important sigh of potential urinary tract malignancy. Therefore, understanding the disease processes and discovering the potential urothelial carcinoma (UC) underlying this important sign is critical. Cystoscopy, urine cytology and imaging are most reliable methods for UC diagnosis, but certain drawbacks exist for these methods, such as invasiveness or inaccuracy. Chromosomal instability (CIN) is a hallmark of human cancer, and it's related with tumor stage and grade. Previous research has proved that analyzing CIN of the DNA extracted from urothelial cells in urine samples seems a promising method for detecting UC. Here the investigators intend to assess CIN's performance for hematuria evaluation.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Hematuria is defined as the presence of 3 or more red blood cells per high-power field (RBC/HPF) under microscopic examination of the urine, which is an important sigh of genitourinary system disease, especially UC. Several methods can be adopted for hematuria evaluation. Cystoscopy is a key component of the hematuria evaluation because it is a reliable way to evaluate the bladder and urethra. Biopsy can also be performed through cystoscopy, making it the "gold standard" for bladder cancer diagnosis. Despite its high reliability and accuracy, it's an invasive examination related with complications such as injury to the urethra, infection, and discomfort. Flat lesions may also be omitted under cystoscopy. Urine cytology is another important method for UC evaluation, but it has a sensitivity of only 15.8%-54.5%.
CIN refers to the ongoing acquisition of genomic alterations, it can range from point mutations to small-scale genomic alterations and gross chromosomal rearrangements. 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of CIN. CIN is presented in UC and it has been adopted as a diagnostic method for UC, such as UroVysion test. Previously, CIN detected by low-coverage whole genome sequencing proved to be a reliable method for UC diagnosis and was named as Urine Exfoliated Cells Copy Number Aberration Detector (UroCAD). In this prospective, multi-canter, observational clinical trial, the investigators intend to assess the possibility of UroCAD as an additional diagnostic tool for hematuria patients by collecting and analyzing 30 ml of urine sample from hematuria patient across 5 centers.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200433
- Changhai Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients presented with hematuria (≥ 3 RBCs/HPF) and patients with malignancy other than urothelial carcinoma in Changhai Hospital, Tongji Hospital, Renji Hospital, First Affiliated Hospital of Xian Jiaotong University, and Gulou Hospital.
Descripción
Inclusion Criteria:
-
Participants aged ≥ 18 years and signed informed consent form.
-
Participants presented with hematuria (≥ 3 RBCs/HPF) and meet one of the following criteria:
- Patients recommended to undergo cystoscopy or ureteroscopy;
- Patients with treatment-naïve, pathology-confirmed urothelial carcinoma;
- Patients diagnosed with benign genitourinary disease.
-
Participants diagnosed with cancer other than urothelial carcinoma.
Exclusion Criteria:
- Participants with history of urothelial carcinoma.
- Participants with urothelial carcinoma accompanied by other malignancy.
- Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor.
- Patients unsuitable for this clinical trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Hematuria patients
Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria. |
The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN. |
|
Non-hematuria patients
Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer. |
The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
sensitivity
Periodo de tiempo: through study completion, an average of 8 months
|
Comparison of the sensitivity of the UroCAD analysis versus clinically-acceptable threshold, defined as 75%. |
through study completion, an average of 8 months
|
|
specificity
Periodo de tiempo: through study completion, an average of 8 months
|
Comparison of the specificity of the UroCAD analysis versus clinically-acceptable threshold, defined as 95%. |
through study completion, an average of 8 months
|
|
Sensitivity among hematuria patients
Periodo de tiempo: through study completion, an average of 8 months
|
Sensitivity of UroCAD in detecting urothelial carcinoma among hematuria patients |
through study completion, an average of 8 months
|
|
Specificity among hematuria patients
Periodo de tiempo: through study completion, an average of 8 months
|
Specificity of UroCAD in detecting urothelial carcinoma among hematuria patients |
through study completion, an average of 8 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Comparison of Sensitivity
Periodo de tiempo: through study completion, an average of 8 months
|
Comparison of the sensitivity of the UroCAD analysis versus urine cytology |
through study completion, an average of 8 months
|
|
Comparison of Specificity
Periodo de tiempo: through study completion, an average of 8 months
|
Comparison of the Specificity of the UroCAD analysis versus urine cytology |
through study completion, an average of 8 months
|
Colaboradores e Investigadores
Publicaciones y enlaces útiles
Publicaciones Generales
- Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018 Mar;15(3):139-150. doi: 10.1038/nrclinonc.2017.198. Epub 2018 Jan 3.
- McDougal, W. Scott, et al. Campbell-Walsh urology 11th Edition review e-book. Elsevier Health Sciences, 2015.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Procesos Patológicos
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Trastornos de la micción
- Neoplasias por tipo histológico
- Hemorragia
- Neoplasias Glandulares y Epiteliales
- Carcinoma
- Condiciones Patológicas, Signos y Síntomas
- Carcinoma De Células De Transición
- Hematuria
Otros números de identificación del estudio
- CH-Hematuria-CIN
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data are not public for privacy protection purpose. Data without private information may be provided on request.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .